,,ii ,calendar ,no4 #daf #aadth ,,congress #b;d ,session ,s4 #bjcj ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,september #ae1 #bjae,mr4 ,bennet 7for himself1 ,mr4 ,burr1 ,ms4 ,warren1 ,mr4 ,hatch1 and ,mr4 ,enzi7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,april #e1 #bjaf,reported by ,mr4 ,alexander1 with an amendment,strike out all after the enacting clause and insert the part printed in italic ,a ,,bill ,to allow the sponsor of an application for the approval of a targeted drug to rely upon data and information with respect to such sponsor's previously approved targeted drugs4 #a4 ,short title ,this ,act may be cited as the ,advancing ,targeted ,therapies for ,rare ,diseases ,act of #bjae4 #b4 ,targeted drugs for rare diseases ,title ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cea et seq47 is amended by inserting after section #ejf;,f the following3 #ejf;,g4 ,targeted drugs for rare diseases 7a7 ,purpose ,the purpose of this section1 through the approach provided for in subsection 7b71 is to-- 7#a7 facilitate the development1 review1 and approval of genetically targeted drugs to address an unmet medical need in one or more patient subgroups 7or gene variant subpopulations7 with respect to rare diseases or conditions that are serious or life-threatening2 and 7#b7 maximize the use of scientific tools or methods1 including surrogate endpoints and other biomarkers for such purposes4 7b7 ,leveraging of data from previously approved drug application or applications ,the ,secretary may1 consistent with applicable standards for approval under this ,act or section #cea of the ,public ,health ,service ,act1 allow the sponsor of a genetically targeted drug to rely upon data and information-- 7#a7 previously developed by the same sponsor 7or another sponsor that has provided the sponsor with a contractual right of reference to such data and information72 and 7#b7 submitted by a sponsor described in paragraph 7#a7 in support of one or more applications previously approved under this ,act or section #cea of the ,public ,health ,service ,act1 for a drug that incorporates or utilizes the same or similar genetically targeted technology1 or the same variant protein targeted technology1 as the drug or drugs that are the subject of an application or applications described in paragraph 7#b74 7c7 ,definitions ,for purposes of this section-- 7#a7 the term genetically targeted drug means a drug which-- 7,a7 is the subject of an application under section #eje7;b77#a7 of this ,act or section #cea7;a7 of the ,public ,health ,service ,act for the treatment of a rare disease or condition 7as such term is defined in section #ebf7 that is serious or life-threatening2 7,b7 incorporates or utilizes a genetically targeted technology or a variant protein targeted technology2 and 7,c7 may result in the modulation 7including suppression1 up-regulation1 or activation7 of the function of a gene or its associated gene product2 7#b7 the term genetically targeted technology means a technology comprising non-replicating nucleic acid or analogous compounds with a common or similar chemistry that is intended to treat one or more subsets of patients with the same disease1 including due to other variants in the same gene2 and 7#c7 the term variant protein targeted technology means a technology or compound that modulates the function of a variant protein1 due to a gene variant1 intended to treat one or more subsets of patients with the same disease1 due to other variants in the same gene4 7d7 ,rule of construction ,nothing in this section shall be construed to-- 7#a7 alter the authority of the ,secretary to approve drugs pursuant to this ,act or section #cea of the ,public ,health ,service ,act 7as authorized prior to the date of enactment of the ,advancing ,targeted ,therapies for ,rare ,diseases ,act of #bjae71 including the standards of evidence1 and applicable conditions1 for approval under such ,act2 or 7#b7 confer any new rights1 beyond those authorized under this section1 with respect to the permissibility of referencing information contained in another application submitted under section #eje7;b77#a7 of this ,act or section #cea7;a7 of the ,public ,health ,service ,act4 4 #a4 ,short title ,this ,act may be cited as the ,advancing ,targeted ,therapies for ,rare ,diseases ,act of #bjaf4 #b4 ,targeted drugs for rare diseases ,subchapter ,b of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;aa et seq47 is amended by inserting after section #ebi the following3 #ebi;,a4 ,targeted drugs for rare diseases 7a7 ,purpose ,the purpose of this section1 through the approach provided for in subsection 7b71 is to-- 7#a7 facilitate the development1 review1 and approval of genetically targeted drugs and variant protein targeted drugs to address an unmet medical need in one or more patient subgroups1 including subgroups of patients with different mutations of a gene1 with respect to rare diseases or conditions that are serious or life-threatening2 and 7#b7 maximize the use of scientific tools or methods1 including surrogate endpoints and other biomarkers for such purposes4 7b7 ,leveraging of data from previously approved drug application or applications ,the ,secretary may1 consistent with applicable standards for approval under this ,act or section #cea7;a7 of the ,public ,health ,service ,act1 allow the sponsor of an application under section #eje7;b77#a7 of this ,act or section #cea7;a7 of the ,public ,health ,service ,act for a genetically targeted drug or a variant protein targeted drug to rely upon data and information-- 7#a7 previously developed by the same sponsor 7or another sponsor that has provided the sponsor with a contractual right of reference to such data and information72 and 7#b7 submitted by a sponsor described in paragraph 7#a7 in support of one or more previously approved applications that were submitted under section #eje7;b77#a7 of this this ,act or section #cea7;a7 of the ,public ,health ,service ,act1 for a drug that incorporates or utilizes the same or similar genetically targeted technology as the drug or drugs that are the subject of an application or applications described in paragraph 7#b7 or for a variant protein targeted drug that is the same or incorporates or utilizes the same variant protein targeted drug1 as the drug or drugs that are the subject of an application or applications described in paragraph 7#b74 7c7 ,definitions ,for purposes of this section-- 7#a7 the term genetically targeted drug means a drug that-- 7,a7 is the subject of an application under section #eje7;b77#a7 of this ,act or section #cea7;a7 of the ,public ,health ,service ,act for the treatment of a rare disease or condition 7as such term is defined in section #ebf7 that is serious or life-threatening2 7,b7 may result in the modulation 7including suppression1 up-regulation1 or activation7 of the function of a gene or its associated gene product2 and 7,c7 incorporates or utilizes a genetically targeted technology2 7#b7 the term genetically targeted technology means a technology comprising non-replicating nucleic acid or analogous compounds with a common or similar chemistry that is intended to treat one or more patient subgroups1 including subgroups of patients with different mutations of a gene1 with the same disease or condition1 including a disease or condition due to other variants in the same gene2 and 7#c7 the term variant protein targeted drug means a drug that-- 7,a7 is the subject of an application under section #eje7;b77#a7 of this ,act or section #cea7;a7 of the ,public ,health ,service ,act for the treatment of a rare disease or condition 7as such term is defined in section #ebf7 that is serious or life-threatening2 7,b7 modulates the function of a product of a mutated gene where such mutation is responsible in whole or in part for a given disease or condition2 and 7,c7 is intended to treat one or more patient subgroups1 including subgroups of patients with different mutations of a gene1 with the same disease or condition4 7d7 ,rule of construction ,nothing in this section shall be construed to-- 7#a7 alter the authority of the ,secretary to approve drugs pursuant to this ,act or section #cea of the ,public ,health ,service ,act 7as authorized prior to the date of enactment of this section71 including the standards of evidence1 and applicable conditions1 for approval under such applicable ,act2 or 7#b7 confer any rights1 beyond those authorized under this ,act or the ,public ,health ,service ,act prior to enactment of this section1 with respect to the permissibility of referencing information contained in another application submitted under section #eje7;b77#a7 of this ,act or section #cea7;a7 of the ,public ,health ,service ,act4 4 ,april #e1 #bjaf,reported with an amendment